Pure Biologics establishes Doto Medical special purpose vehicle

Pure Biologics establishes the Doto Medical special purpose vehicle and signs an agreement with the renowned international business advisor Clairfield Partners to accelerate the commercialization of the PB103 aptamer project.

News

Inquiries

Pure Biologics webinar – year summary and project updates

25 November

2022

Pure Biologics webinar – year summary and project updates

Webinar with the management.

Two Pure Biologics projects qualified for funding in the Medical Research Agency grant call

22 November

2022

Two Pure Biologics projects qualified for funding in the Medical Research Agency grant call

Two projects have been qualified for funding under the Medical Research Agency (Agencja Badań Medycznych) grant call for the development of targeted or personalized medicine based on cell therapies or protein products.

Webinar with the Management Board organized by “Strefa Inwestorow”

29 September

2022

Webinar with the Management Board organized by “Strefa Inwestorow”

Webinar with Pure Biologics, Wednesday 05/10/2022

Initiation of the in vivo stage in the PB003

22 September

2022

Initiation of the in vivo stage in the PB003

The first in vivo studies for the PB003 project were launched by administering the first dose of a model molecule to test animals.

Pure Biologics optimizes the PB004 plan to obtain relevant clinical data faster

20 September

2022

Pure Biologics optimizes the PB004 plan to obtain relevant clinical data faster

Obtaining the results of phase 0 will allow us to obtain the first information about the effectiveness of the compound in humans faster than by the classic approach, based on phase I and II clinical trials.

9 October

2020

Pure Biologics establishes Doto Medical special purpose vehicle

Pure Biologics webinar – year summary and project updates

Two Pure Biologics projects qualified for funding in the Medical Research Agency grant call

Webinar with the Management Board organized by “Strefa Inwestorow”

Initiation of the in vivo stage in the PB003

Pure Biologics optimizes the PB004 plan to obtain relevant clinical data faster

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/2/20 25.01.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/1/20 21.01.2020